ANI Pharmaceuticals (NASDAQ:ANIP) CEO Nikhil Lalwani Sells 5,400 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total value of $401,220.00. Following the sale, the chief executive officer directly owned 344,489 shares in the company, valued at approximately $25,595,532.70. This represents a 1.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $74.56 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The stock has a 50 day simple moving average of $79.93 and a 200 day simple moving average of $78.75. ANI Pharmaceuticals, Inc. has a 52-week low of $70.15 and a 52-week high of $99.50. The firm has a market capitalization of $1.71 billion, a PE ratio of 16.07 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. During the same period in the prior year, the business earned $1.80 EPS. ANI Pharmaceuticals’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ANIP. California State Teachers Retirement System lifted its stake in ANI Pharmaceuticals by 7,977.4% in the 2nd quarter. California State Teachers Retirement System now owns 1,983,574 shares of the specialty pharmaceutical company’s stock valued at $164,200,000 after purchasing an additional 1,959,017 shares during the last quarter. Vanguard Group Inc. raised its stake in ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after buying an additional 27,598 shares during the last quarter. State Street Corp lifted its stake in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after purchasing an additional 15,496 shares during the period. UBS Group AG lifted its stake in ANI Pharmaceuticals by 45.8% in the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of ANI Pharmaceuticals by 19.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock valued at $43,399,000 after acquiring an additional 91,153 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ANIP shares. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Guggenheim reduced their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Canaccord Genuity Group dropped their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Finally, Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.